Search results
Showing 101 to 132 of 132 results for cbt
This quality standard covers assessing and managing borderline and antisocial personality disorders. It describes high-quality care in priority areas for improvement.
View quality statements for QS88Show all sections
Sections for QS88
- Quality statements
- Quality statement 1: Structured clinical assessment
- Quality statement 2: Psychological therapies – borderline personality disorder
- Quality statement 3: Psychological therapies – antisocial personality disorder
- Quality statement 4: Pharmacological interventions
- Quality statement 5: Managing transitions
- Quality statement 6: Education and employment goals
- Quality statement 7: Staff supervision
Why this is important:- There is evidence for the effectiveness of both CBT and medication, in particular SSRIs, in the treatment of...
versus generic CBT for children and young people with social anxiety disorder:- What is the clinical and cost effectiveness of specific...
Psychological interventions:- Are the psychological interventions [cognitive behavioural therapy] (CBT), hypnotherapy and...
headache disorders:- Does a psychological intervention such as cognitive behavioural therapy (CBT) improve headache...
should be tested using an RCT design with standard care (for example, group CBT) as the comparison. It should report short- and...
symptoms in people with psychosis and schizophrenia:- What is the benefit of a CBT-based trauma reprocessing intervention on PTSD...
is the relative effectiveness of sertraline compared with cognitive behavioural therapy (CBT) in people with generalised...
clinical and cost effectiveness for family intervention combined with individual CBT in the treatment of children and young people...
interventions most likely to have an impact is family intervention and individual CBT. The key outcomes should include symptoms, relapse...
versus group CBT for children and young people with social anxiety disorder:- What is the clinical and cost effectiveness of individual...
even with the most effective current treatment (for example, cognitive behavioural therapies and social network and environment-based...
(GAD), what is the clinical and cost effectiveness of two cognitive behavioural therapy (CBT) based low-intensity...
disorder, what is the clinical and cost effectiveness of two cognitive behavioural therapy (CBT) based low-intensity...
Is acupuncture effective in reducing alcohol consumption compared with standard care?
acamprosate or naltrexone) and psychological treatments (for example, cognitive behavioural therapies and social network and...
or lack of efficacy. There is evidence that psychological interventions (CBT and family intervention) as an adjunct to antipsychotic...
This quality standard covers treating and managing psychosis and schizophrenia in adults (aged 18 and over) in primary, secondary and community care. It also includes support for the families and carers of people with psychosis or schizophrenia. It describes high-quality care in priority areas for improvement.
View quality statements for QS80Show all sections
Sections for QS80
- Quality statements
- Quality statement 1: Referral to early intervention in psychosis services
- Quality statement 2: Cognitive behavioural therapy
- Quality statement 3: Family intervention
- Quality statement 4: Treatment with clozapine
- Quality statement 5: Supported employment programmes
- Quality statement 6: Assessing physical health
- Quality statement 7: Promoting healthy eating, physical activity and smoking cessation
Nalmefene for reducing alcohol consumption in people with alcohol dependence (TA325)
Evidence-based recommendations on nalmefene (Selincro) for reducing alcohol consumption in adults with alcohol dependence.
This guideline covers identifying, assessing and managing alcohol-use disorders (harmful drinking and alcohol dependence) in adults and young people aged 10 to 17 years. It aims to reduce harms (such as liver disease, heart problems, depression and anxiety) from alcohol by improving assessment and setting goals for reducing alcohol consumption.
Acoustic CR Neuromodulation for adults with chronic subjective tonal tinnitus (MIB5)
NICE has developed a Medtech Innovation Briefing (MIB) on the Acoustic CR Neuromodulation system
Psychosis and schizophrenia in adults: prevention and management (CG178)
This guideline covers recognising and managing psychosis and schizophrenia in adults. It aims to improve care through early recognition and treatment, and by focusing on long-term recovery. It also recommends checking for coexisting health problems and providing support for family members and carers.
This guideline covers planning and delivering multi-agency services for domestic violence and abuse. It aims to help identify, prevent and reduce domestic violence and abuse among women and men in heterosexual or same-sex relationships, and among young people.
Endoscopic thoracic sympathectomy for primary facial blushing (HTG331)
Evidence-based recommendations on endoscopic thoracic sympathectomy for primary facial blushing. This involves cutting off nerve signals to stop the blushing.
This quality standard covers identifying and managing anxiety disorders in adults, young people and children in primary, secondary and community care. It covers a range of anxiety disorders, including generalised anxiety disorder, social anxiety disorder, post-traumatic stress disorder, panic disorder, obsessive-compulsive disorder and body dysmorphic disorder. It describes high-quality care in priority areas for improvement.
View quality statements for QS53Show all sections
Social anxiety disorder: recognition, assessment and treatment (CG159)
This guideline covers recognising, assessing and treating social anxiety disorder (also known as ‘social phobia’) in children and young people (from school age to 17 years) and adults (aged 18 years and older). It aims to improve symptoms, educational, occupational and social functioning, and quality of life in people with social anxiety disorder.
Depression in adults with a chronic physical health problem: recognition and management (CG91)
This guideline covers identifying, treating and managing depression in people aged 18 and over who also have a chronic physical health problem such as cancer, heart disease or diabetes. It aims to improve the care of people with a long-term physical health problem, which can cause or exacerbate depression. This has the potential to increase their quality of life and life expectancy.
This guideline covers using psychosocial interventions to treat adults and young people over 16 who have a problem with or are dependent on opioids, stimulants or cannabis. It aims to reduce illicit drug use and improve people’s physical and mental health, relationships and employment.
Obsessive-compulsive disorder and body dysmorphic disorder: treatment (CG31)
This guideline covers recognising, assessing, diagnosing and treating obsessive-compulsive disorder and body dysmorphic disorder in adults, young people and children (aged 8 years and older). It aims to improve the diagnosis and treatment of obsessive-compulsive disorder and body dysmorphic disorder. It includes recommendations on how families and carers may be able to support people with either of these conditions, and how they can get support for themselves.
In development Reference number: GID-HTE10068 Expected publication date: 06 January 2027
We have moved Health technology evaluation 3 to become HealthTech guidance 660. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Computerised cognitive behaviour therapy (CCBT) for the treatment of depression and anxiety (TA51)
This guidance has been updated and replaced by NICE technology appraisal guidance 97.
Computerised cognitive behaviour therapy for depression and anxiety (TA97)
The guidance was withdrawn in July 2018 to allow OCFighter to be considered for an improving access to psychological therapies assessment briefing. If OCFighter is not selected, it may be considered for a medtech innovation briefing.